手机镜头商大立光11月营收按年升66% 连续四个月创新高
受惠於iPhone11热销,舜宇光学(02382.HK)同业大立光(03008.TW)昨日公布11月合并营收66.56亿新台币(下同),按月升0.5%,连续四个月创新高,亦较去年同期40.08亿元按年升66%,优於预期。大立光今年首11月合并营收556.67亿元,年增19.14%。
据台湾《经济日报》报道,大立光表示目前产能持续满载,但因拉货高峰已过,12月拉货动能将较11月减缓。而大立光执行长林恩平日前表示,7P(七片塑胶镜片)的案子持续增加中。他透露现时正在做8P(八片塑胶镜片)的案子。外资看好,明年新款iPhone有机会搭载四镜头或采用7P设计。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.